Clinical trials for Head and neck cancer
106 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT04585750
#2023-504251-27-00
Phase 2 autres tumeurs solides
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
#NCT07213817
#2025-522139-33-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Ipsen
Phase 1 / Phase 2
Head and neck cancer
#NCT06795412
#2025-521828-30-00
Étude de phase 1/2 du PYX-201 en association avec le pembrolizumab dans les tumeurs solides avancées
Partie 1 Cancer tête et cou
Required histologic types
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
2
3 or more
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
Pyxis Oncology, Inc
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
#NCT06923761
#2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2
Lung cancer
Colon cancer
Rectal cancer
Stomach and esophageal cancer
Head and neck cancer
#NCT07151040
#2024-519639-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
One-carbon Therapeutics AB
Phase 1 / Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
#NCT05118789
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Head and neck cancer
#NCT06385080
#2023-508418-40-00
Cohorte 4 Carcinome épidermoïde de la tête et du cou récidivant/métastatique
Required histologic types
Oropharynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required P16 statuses
P16 Positive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Janssen
Phase 1 / Phase 2
Head and neck cancer
#NCT06385080
#2023-508418-40-00
Cohorte 5 Carcinome épidermoïde de la tête et du cou récidivant/métastatique
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Janssen
Phase 1 / Phase 2
Head and neck cancer
#NCT06385080
#2023-508418-40-00
Cohorte 6 Carcinome épidermoïde de la tête et du cou localement avancé
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required P16 statuses
P16 Negative
5 recruiting sites
Janssen
Phase 1 / Phase 2
Lung cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
#NCT06923761
#2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Esophagus
Invasive bladder cancer
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Required histologic sub types
Adenocarcinoma
Squamous cell carcinoma
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics